SUPN
HealthcareSupernus Pharmaceuticals, Inc.
$49.40
$-0.07 (-0.14%)
Jan 5, 2026
Price History (1Y)
Analysis
Supernus Pharmaceuticals, Inc. is a healthcare company operating in the drug manufacturers - specialty & generic industry. It has a market capitalization of $2.83 billion and annual revenues of $681.54 million, employing 674 individuals. The company's financial health indicates profitability challenges, with a net income loss of $19.11 million and an operating margin of 4.4%. However, its gross margin stands at 88.9% and free cash flow is $120.81 million. Supernus has a debt-to-equity ratio of 4.02 and maintains a current ratio of 1.80. Its return on equity (ROE) is -1.9%, while the return on assets (ROA) stands at 1.5%. Valuation metrics include a forward P/E ratio of 11.63, an EV/EBITDA ratio of 21.84, and a price-to-book ratio of 2.69. The company's revenue growth rate is 9.3% year-over-year, while earnings growth data is not available.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Visit website →Key Statistics
- Market Cap
- $2.83B
- P/E Ratio
- N/A
- 52-Week High
- $57.65
- 52-Week Low
- $29.16
- Avg Volume
- 827.47K
- Beta
- 0.68
Company Info
- Exchange
- NGM
- Country
- United States
- Employees
- 674